

Amendments to the Claims:

This listing of claims will replace all other all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1. (Withdrawn): A method for inducing or modulating T or B cell tolerance to donor cells, tissue or organ in a recipient comprising administering to the recipient a LFA-1 inhibitor in combination with a costimulation inhibitor and/or a mTOR inhibitor.

Claim 2. (Currently Amended): A method for inducing hematopoietic chimerism in a recipient of cells, tissue or an organ transplant from a donor comprising additionally administering to the recipient

- i) bone marrow cells or other precursor cells from the donor; and
- ii) an anti-LFA-1 inhibitor antibody in combination with at least one co-agent selected from an anti-CD154 antibody ~~costimulation inhibitor~~ and a ~~mTOR inhibitor~~ 40-O-(2-hydroxyethyl)-rapamycin.

Claim 3. (Withdrawn): A method for treating diabetes comprising administering to a subject in need of such a treatment, in addition to i) and ii) as defined in claim 2, iii) allogeneic pancreatic islet cells or other insulin producing cells.

Claim 4. (Withdrawn): A method for inducing apoptosis of activated T cells in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 5. (Withdrawn): A method for delaying progression of, attenuating severity of, suppressing, mitigating or treating immune disorders or diseases in a subject by inducing or modulating immune tolerance in said subject, the immune disorders or diseases being dependent on activation of lymphoid cells, which method comprises administering to said subject a therapeutically effective amount of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 6. (Withdrawn): A method for treating malignancies in a subject in need

thereof, comprising administering to said subject cells i) and a product ii) as defined in claim 2, in order to achieve full or mixed hematopoietic chimerism.

Claim 7. (Withdrawn): A method for treating non-malignant diseases of bone marrow failure, comprising administering to said subject cells i) and a product ii) as defined in claim 2, in order to achieve full or mixed hematopoietic chimerism.

Claim 8. (Withdrawn): A method according to-claim 1, further comprising administering to the recipient or subject 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.

Claim 9. (Withdrawn): Use of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor in a method according claim 1.

Claim 10. (Withdrawn): A pharmaceutical combination comprising

- a) a LFA-1 inhibitor; and
- b) at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 11. (Withdrawn): A combination comprising

- a) a LFA-1 inhibitor; and
- b) at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor for use in a method according to claim 1.

Claim 12. (Withdrawn): A combination according to claim 10, further comprising 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.

Claim 13. (Previously Presented): The method according to claim 2, further comprising administering to the recipient 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.